Novocure (NSDQ:NVCR) said today that it kicked off a Phase 3 pivotal trial testing its Tumor Treating Fields therapy combined with paclitaxel in people with recurrent, platinum-resistant ovarian cancer. The 540-patient trial has a primary endpoint of overall survival, with secondary endpoints that include progression-free survival, objective response rate, severity and frequency of adverse events and […]
Novocure shares dip on Q4, 2018 earnings miss
Shares in Novocure (NSDQ:NVCR) fell slightly today after the medical device maker missed expectations on Wall Street with its fourth quarter and full year 2018 earnings release. The St. Helier, Jersey-based company posted losses of $15.6 million, or 17¢ per share, on sales of $69.7 million for the three months ended December 31, seeing losses grow […]
Boston Scientific shares tick up after Q4 prelims meet estimates | Wall Street Beat
Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. […]
Novocure backs $2m in brain cancer research grants
Novocure (NSDQ:NVCR) today, along with the American Association for Cancer Research, announced four inaugural Tumor Treating Fields research grants totaling more than $1.5 million. The St. Helier, Jersey-based company said that the newly launched grants include the AACR-Novocure Tumor Treating Fields Research Grant, the AACR-Novocure Career Development Award for Tumor Treating Fields Research, the AACR-Novocure Tumor Treating Fields Research Fellowship and […]
Novocure touts analysis of pivotal glioblastoma trial results
Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma. The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received […]
NovoCure slides on Q3 sales miss
NovoCure (NSDQ:NVCR) shares took a hit today, despite lower-than-forecast losses, after the company reported financial results that missed expectations for third-quarter sales. Losses were up 1.7% to -$11.7 million, or -13¢ per share, on sales growth of 29.2% to $64.8 million for the three months ended Sept. 30, compared with Q3 2017. The consensus estimate on Wall […]
Novocure touts results from glioblastoma TTF trial analysis
NovoCure (NSDQ:NVCR) yesterday released results from a post-hoc analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma, touting an association between higher doses of Tumor Treating Fields and improved overall survival. The analysis explored patient data from 317 qualified individuals in the TTF treatment arm of the St. Helier, Jersey-based company’s EF-14 phase […]
Novocure touts Phase II pancreatic cancer pilot study
Novocure (NSDQ:NVCR) today touted the results of a Phase II pilot trial designed to test the feasibility, safety and efficacy of its Tumor Treating Fields therapy in patients with unresectable, advanced pancreatic cancer. The St. Helier, N.J.-based company’s Optune device uses electric fields, called Tumor Treating Fields, to disrupt cell division, inhibit tumor growth and trigger […]
Novocure wins CMS review of Optune glioblastoma Tx
NovoCure (NSDQ:NVCR) said today that the durable medical equipment Medicare Administrative Contractors accepted a new local coverage determination reconsideration request for the treatment of newly diagnosed glioblastoma with its Optune system. The St. Helier, Jersey-based company said it plans to “take steps to publish a final LCD for newly diagnosed GBM,” and per the Centers for […]
Novocure inks Chinese collaborative dev, commercialization deal with Zai Lab
Novocure (NSDQ:NVCR) said today it inked a $15 million licensing agreement with Shanghai-based biopharma company Zai Lab to offer its Optune technology on the Chinese market and accelerate clinical trial enrollment in the region. The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. Read the whole story on […]
Novocure touts combined TTF, chemotherapy mesothelioma study data
Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival. Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a […]
- 1
- 2
- 3
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube